Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
News|Articles|February 26, 2025
- Vol. 26/No. 4
- Volume 26
- Issue 4
Tips for Tomorrow: What 4 Experts Wish They Knew Earlier About ADCs
Author(s)Megan Hollasch
Fact checked by: Caroline Seymour
Clinicians with years of ADC therapy experience provide insights on the drug class and what is most important to keep in mind when treating patients.
Advertisement
Advertisement
Although antibody-drug conjugates (ADCs) have been approved in select tumor types for years now, the 2024 tumor-agnostic approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for select patients has provided the first ever ADC option in many cancers.1
Related to this article
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement